Ranbaxy Laboratories Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ranbaxy Laboratories Limited
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
An online pharmacy that tests medications before dispensing them advocated for regulations requiring independent testing and verification of the chemical content of pharmaceuticals; it also alleged that the US FDA’s testing method for evaluating the carcinogenic risk of metformin needs refinement.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.